ADMA Biologics Investors Face August 10 Deadline in Securities Lawsuit

The litigation alleges that ADMA Biologics misled the market during the specified class period by failing to disclose critical operational shortcomings. According to the complaint, the company allegedly engaged in an undisclosed related party transaction and utilized channel stuffing to artificially inflate reported revenue figures. Furthermore, the suit claims that the firm lacked the necessary internal controls, rendering its public statements regarding business health and future prospects materially false or misleading.

Investors who incurred losses during this period may be eligible for compensation through a contingency fee arrangement, meaning no out-of-pocket costs are required to participate. While the lawsuit has been filed, no class has yet been certified. Individuals may choose to retain their own counsel, remain as absent class members, or move the court to serve as a lead representative. Those interested in the case can contact Phillip Kim at The Rosen Law Firm via their website or by calling 866-767-3653.